Oclaro Acquires Mintera to Expand Optical Telecommunication Networks

Laser components and optical communications provider, Oclaro, announced that it has acquired an optical transport solution firm, Mintera Corporation. The acquisition will allow Oclaro to expand its high-speed telecommunication portfolio.

The company will provide sub-systems and components that will cover key modulation technologies required for high-speed data transmission in ultra Long-Haul (ULH), long-haul (LH), metro and regional networks.

According to Infonetics Research, the 40 Gbps telecommunicating market is estimated to reach $150 million by 2011 and will be split equally between Differential Quadrature Phase Shift Keying (DQPSK) and Differential Phase Shift Keying (DPSK) technologies. Mintera has attained a significant market share for its 40 Gbps Adaptive DPSK module. Oclaro will leverage this market acceptance by including Mintera’s DPSK solutions in its DQPSK portfolio.

Oclaro expects that the 40 Gbps Differential Phase Shift Keying transmission market will shift towards the Coherent technology market by 2011. The 40 Gbps PM-QPSK modules will be manufactured in the mid-half of 2011 and will further boost Oclaro’s lead position in the 100 Gbps market.

Oclaro’s Chief Executive Officer, Alain Couder, stated that the acquisition marks a significant step for the company and will enable them to widen their product portfolio and build a lead position in the 40 Gbps metro and regional networks.

The President of Mintera, Terry Unter, stated that the acquisition will allow them to increase the sales of their technologies and products.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.